Trends in antipsychotic drug use by very young, privately insured children
- PMID: 20215922
- DOI: 10.1097/00004583-201001000-00005
Trends in antipsychotic drug use by very young, privately insured children
Abstract
Objective: This study describes recent trends and patterns in antipsychotic treatment of privately insured children aged 2 through 5 years.
Method: A trend analysis is presented of antipsychotic medication use (1999-2001 versus 2007) stratified by patient characteristics. Data are analyzed from a large administrative database of privately insured individuals. Participants were privately insured children, aged 2 through 5 years, with 12 months of continuous service enrollment in 1999-2001 (N = 400,196) or 2007 (N = 755,793). The main outcomes are annualized rates of antipsychotic use and adjusted rate ratios (ARR) of year effect on rate of antipsychotic use adjusted for age, sex, and treated mental disorder.
Results: The annualized rate of any antipsychotic use per 1,000 children increased from 0.78 (95% confidence interval [CI] 0.69-0.88) (1999-2001) to 1.59 (95% CI 1.50-1.68) (2007) (ARR 1.76, 95% CI 1.56-2.00). Significant increases in antipsychotic drug use were evident for boys (ARR 1.66, 95% CI 1.44-1.90) and girls (ARR 2.26, 95% CI 1.70-3.01) and for children diagnosed with several different psychiatric disorders. Among antipsychotic-treated children in the 2007 sample, pervasive developmental disorder or mental retardation (28.2%), attention deficit/hyperactivity disorder (ADHD) (23.7%), and disruptive behavior disorder (12.9%) were the most common clinical diagnoses. Fewer than one-half of antipsychotic-treated young children received a mental health assessment (40.8%), a psychotherapy visit (41.4%), or a visit with a psychiatrist (42.6%) during the year of antipsychotic use.
Conclusions: Despite increasing rates of antipsychotic use by very young children, provision of formal mental health services remains sparse. These service patterns highlight a critical need to improve the availability of specialized and well integrated mental health care for very young children with serious mental health problems.
Comment in
-
A perilous disconnect: antipsychotic drug use in very young children.J Am Acad Child Adolesc Psychiatry. 2010 Jan;49(1):3-6. J Am Acad Child Adolesc Psychiatry. 2010. PMID: 20215919 No abstract available.
Similar articles
-
Trends in Antipsychotic Medication Use in Young Privately Insured Children.J Am Acad Child Adolesc Psychiatry. 2021 Jul;60(7):877-886. doi: 10.1016/j.jaac.2020.09.023. Epub 2020 Oct 20. J Am Acad Child Adolesc Psychiatry. 2021. PMID: 33091567 Free PMC article.
-
Antipsychotic prescribing for behavioral disorders in US youth: physician specialty, insurance coverage, and complex regimens.Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):26-34. doi: 10.1002/pds.3897. Epub 2015 Oct 28. Pharmacoepidemiol Drug Saf. 2016. PMID: 26507224
-
Treatment of Young People With Antipsychotic Medications in the United States.JAMA Psychiatry. 2015 Sep;72(9):867-74. doi: 10.1001/jamapsychiatry.2015.0500. JAMA Psychiatry. 2015. PMID: 26132724
-
Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.Dev Disabil Res Rev. 2010;16(3):273-82. doi: 10.1002/ddrr.120. Dev Disabil Res Rev. 2010. PMID: 20981766 Review.
-
Use of medication in pervasive developmental disorders.Psychiatr Clin North Am. 1991 Mar;14(1):165-82. Psychiatr Clin North Am. 1991. PMID: 1675463 Review.
Cited by
-
Early-life risperidone alters locomotor responses to apomorphine and quinpirole in adulthood.Behav Brain Res. 2024 Sep 13;473:115171. doi: 10.1016/j.bbr.2024.115171. Epub 2024 Jul 31. Behav Brain Res. 2024. PMID: 39094954
-
Five-year trend of antipsychotic prescription practices in a district Hospital in Ghana: A retrospective study.Neuropsychopharmacol Rep. 2023 Sep;43(3):434-439. doi: 10.1002/npr2.12372. Epub 2023 Aug 13. Neuropsychopharmacol Rep. 2023. PMID: 37574802 Free PMC article.
-
Emergence of psychiatric adverse events during antipsychotic treatment in AP-naïve children and adolescents.Child Adolesc Psychiatry Ment Health. 2022 Nov 12;16(1):83. doi: 10.1186/s13034-022-00517-3. Child Adolesc Psychiatry Ment Health. 2022. PMID: 36371250 Free PMC article.
-
Effects of Risperidone and Prenatal Poly I:C Exposure on GABAA Receptors and AKT-GSK3β Pathway in the Ventral Tegmental Area of Female Juvenile Rats.Biomolecules. 2022 May 23;12(5):732. doi: 10.3390/biom12050732. Biomolecules. 2022. PMID: 35625659 Free PMC article.
-
Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):93-102. doi: 10.1016/j.jaac.2021.04.010. Epub 2021 May 4. J Am Acad Child Adolesc Psychiatry. 2022. PMID: 34256967 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
